Monophosphoryl Lipid A-Adjuvanted Virosomes with Ni-Chelating Lipids for Attachment of Conserved Viral Proteins as Cross-Protective Influenza Vaccine

Wei Dong, Yoshita Bhide, Sonny Marsman, Marijke Holtrop, Tjarko Meijerhof, Jacqueline de Vries-Idema, Aalzen de Haan, Anke Huckriede*

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

16 Citaten (Scopus)
338 Downloads (Pure)


BACKGROUND: Induction of CD8+ cytotoxic T cells (CTLs) to conserved internal influenza antigens, such as nucleoprotein (NP), is a promising strategy for the development of cross-protective influenza vaccines. However, influenza NP protein alone cannot induce CTL immunity due to its low capacity to activate antigen-presenting cells (APCs) and get access to the MHC class I antigen processing pathway.

METHODS: To facilitate the generation of NP-specific CTL immunity we developed a novel influenza vaccine consisting of virosomes with the Toll-like receptor 4 (TLR4) ligand monophosphoryl lipid A (MPLA) and the metal-ion-chelating lipid DOGS-NTA-Ni incorporated in the membrane.

RESULTS: In vitro, virosomes with incorporated MPLA induced stronger activation of APCs than unadjuvanted virosomes. Virosomes modified with DOGS-NTA-Ni showed high conjugation efficacy for his-tagged proteins and facilitated efficient uptake of conjugated proteins by APCs. Immunization of mice with MPLA-adjuvanted virosomes with attached NP resulted in priming of NP-specific CTLs while MPLA-adjuvanted virosomes with admixed NP were inefficient in priming CTLs. Both vaccines induced equally high titers of NP-specific antibodies. When challenged with heterosubtypic influenza virus, mice immunized with virosomes with attached or admixed NP were protected from severe weight loss. Yet, unexpectedly, they showed more weight loss and more severe disease symptoms than mice immunized with MPLA-virosomes without NP.

CONCLUSIONS: Taken together, these results indicate that virosomes with conjugated antigen and adjuvant incorporated in the membrane are effective in priming of CTLs and eliciting antigen-specific antibody responses in vivo. However, for protection from influenza infection NP-specific immunity appeared not to be advantageous.

Originele taal-2English
Aantal pagina's9
TijdschriftBiotechnology Journal
Nummer van het tijdschrift4
Vroegere onlinedatum26-dec.-2017
StatusPublished - apr.-2018

Citeer dit